|Day Low/High||6.70 / 6.99|
|52 Wk Low/High||5.60 / 10.74|
Totaling $25.5 M in payments from HTIT received to date
Payment comes in wake of positive topline phase IIB results
All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT
Patent addresses platform technology for oral insulin capsule ORMD-0801
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share
180 Patients Expected to be Enrolled in Study
These under-$10 stocks are within range of triggering breakout trades.
These under-$10 stocks are within range of triggering big breakout trades.
Company's largest study to date with over 30 clinical sites in the United States to participate
Company's largest study to date with over 30 clinical sites in the U.S. to participate